Funds and ETFs AstraZeneca PLC

AZN

GB0009895292

Name	Weight	AuM	1st Jan change	Investor Rating
AMUNDI INDEX MSCI WORLD UCITS ETF - EUR	0.38%	1,166 M€	+0.26%	-
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.38%	607 M€	+0.05%	-
VANECK MULTI-ASSET GROWTH ALLOCATION UCITS ETF - EUR	0.37%	0 M€	+3.67%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.28%	0 M€	+8.16%	-
LEVERAGE SHARES 3X LONG TOTAL WORLD ETP SECURITIES - USD	0.27%	0 M€	0.00%	-
VANECK MULTI-ASSET BALANCED ALLOCATION UCITS ETF - EUR	0.25%	0 M€	+3.03%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.25%	0 M€	+7.51%	-
INDEXIQ FACTORS SUSTAINABLE EUROPE EQUITY UCITS ETF - EUR	0.21%	0 M€	+7.04%
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.18%	0 M€	+5.64%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.18%	0 M€	+4.96%	-
VANECK MULTI-ASSET CONSERVATIVE ALLOCATION UCITS ETF - EUR	0.17%	0 M€	+1.14%	-
IMGP RBA RESPONSIBLE GLOBAL ALLOCATION ETF - USD	0.17%	7 M€	+0.11%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.14%	0 M€	+2.65%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0.14%	0 M€	+3.44%	-
CSIF (IE) MSCI WORLD ESG LEADERS MINIMUM VOLATILITY BLUE UCITS ETF B - USD	0.13%	0 M€	+6.67%
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	0.09%	0 M€	+3.53%	-
ADAPTIVE GROWTH OPPORTUNITIES ETF - USD	0.08%	0 M€	+3.48%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.07%	0 M€	+0.53%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR	0.07%	0 M€	+0.56%	-
CI MARRET ALTERNATIVE ABSOLUTE RETURN BOND ETF - USD	0.00%	0 M€	0.00%	-
CI ALTERNATIVE DIVERSIFIED OPPORTUNITIES FUND ETF - USD HEDGED	0.00%	0 M€	-1.79%	-
CI ALTERNATIVE DIVERSIFIED OPPORTUNITIES FUND - CAD	0.01%	0 M€	-1.96%	-
CI MARRET ALTERNATIVE ABSOLUTE RETURN BOND ETF - CAD	0.01%	0 M€	-3.22%	-

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-05-19 - American Thoracic Society Conference - Abstarct Number - P297

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

152 USD

Average target price

165.3 USD

Spread / Average Target

+8.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+14.32%	235B
ELI LILLY AND COMPANY	+33.43%	690B
NOVO NORDISK A/S	+26.43%	546B
JOHNSON & JOHNSON	-5.12%	358B
MERCK & CO., INC.	+19.59%	323B
ABBVIE INC.	+4.89%	287B
NOVARTIS AG	+5.79%	199B
ROCHE HOLDING AG	-9.49%	195B
AMGEN INC.	+4.26%	161B
PFIZER, INC.	-3.54%	159B

Other Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:21 2024-05-07 am EDT			5-day change	1st Jan Change
12,118 ^GBX	+0.56%		+0.46%	+14.32%

May. 07	AstraZeneca to withdraw COVID-19 vaccine globally, Telegraph reports	RE
May. 07	AstraZeneca to withdraw Covid vaccine worldwide, The Telegraph reports	RE